Recursion Pharmaceuticals, Inc. ( RXRX) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM EST All right. Good morning, again, for I see some familiar face in the last one, but thanks ...
EPS estimates have risen 2.6% over the past 60 days, though revenue expectations have remained essentially flat over the same period. Eight analysts rate the stock a Buy, with a mean price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results